JP2005528359A5 - - Google Patents

Download PDF

Info

Publication number
JP2005528359A5
JP2005528359A5 JP2003577780A JP2003577780A JP2005528359A5 JP 2005528359 A5 JP2005528359 A5 JP 2005528359A5 JP 2003577780 A JP2003577780 A JP 2003577780A JP 2003577780 A JP2003577780 A JP 2003577780A JP 2005528359 A5 JP2005528359 A5 JP 2005528359A5
Authority
JP
Japan
Prior art keywords
transdermal
depression
dosage
buprenorphine
transdermal dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003577780A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005528359A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/008796 external-priority patent/WO2003079945A1/en
Publication of JP2005528359A publication Critical patent/JP2005528359A/ja
Publication of JP2005528359A5 publication Critical patent/JP2005528359A5/ja
Pending legal-status Critical Current

Links

JP2003577780A 2002-03-20 2003-03-20 うつ病の治療のためのブプレノルフィンの投与方法 Pending JP2005528359A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36635802P 2002-03-20 2002-03-20
PCT/US2003/008796 WO2003079945A1 (en) 2002-03-20 2003-03-20 Method of administering buprenorphine to treat depression

Publications (2)

Publication Number Publication Date
JP2005528359A JP2005528359A (ja) 2005-09-22
JP2005528359A5 true JP2005528359A5 (https=) 2006-05-11

Family

ID=28454789

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003577780A Pending JP2005528359A (ja) 2002-03-20 2003-03-20 うつ病の治療のためのブプレノルフィンの投与方法

Country Status (12)

Country Link
US (1) US20030181475A1 (https=)
EP (1) EP1485051B1 (https=)
JP (1) JP2005528359A (https=)
AT (1) ATE394097T1 (https=)
AU (1) AU2003224742A1 (https=)
CY (1) CY1108217T1 (https=)
DE (1) DE60320770D1 (https=)
DK (1) DK1485051T3 (https=)
ES (1) ES2305457T3 (https=)
PT (1) PT1485051E (https=)
SI (1) SI1485051T1 (https=)
WO (1) WO2003079945A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
EP1913938A1 (en) * 2002-12-13 2008-04-23 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
AU2003297073A1 (en) * 2002-12-13 2004-07-09 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
KR101159828B1 (ko) 2003-04-30 2012-07-04 퍼듀 퍼머 엘피 활성제 구성요소 및 활성제 층의 원위부에 억제제 구성요소를 포함하는 내변조성 경피제형
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
SI1646328T1 (sl) 2003-07-25 2008-02-29 Euro Celtique Sa Zdravljenje pri odvajanju od odvisnosti
DE10340428B4 (de) * 2003-09-02 2015-02-12 Acino Ag Opioides Analgetikum enthaltende transdermale Formulierung
FR2865650B1 (fr) * 2004-01-30 2008-06-13 Biocortech Utilisation du 14,15 dihydro 20,21-dinoreburnamenin14-ol pour traiter et/ou prevenir les depressions majeures et les desordres du cycle veille-sommeil
DE102004045599A1 (de) * 2004-09-17 2006-03-23 Grünenthal GmbH System zur sequentiellen, transdermalen Verabreichung von systemisch wirksamen Substanzen
DE102005007859A1 (de) * 2005-02-21 2006-08-24 Lts Lohmann Therapie-Systeme Ag Vefahren für eine medikamentöse Kombinations-Behandlung, sowie hierfür geeignete Arzneimittel-Kombinationen
DE102006011340A1 (de) * 2006-03-09 2007-09-20 Grünenthal GmbH Wirkstoffhaltige Pflaster mit verbesserter Handhabung
TR201908514T4 (tr) 2009-12-04 2019-07-22 Alkermes Pharma Ireland Ltd İlaç doz aşimi tedavi̇si̇ i̇çi̇n morfi̇nan türevleri̇
US8778960B2 (en) 2010-08-23 2014-07-15 Alkermes Pharma Ireland Limited Methods for treating antipsychotic-induced weight gain
WO2013042054A1 (en) * 2011-09-19 2013-03-28 Carmel - Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
AU2012351805B2 (en) * 2011-12-15 2016-04-21 Alkermes Pharma Ireland Limited Samidorphan (ALKS 33) in combination with opioid agonists
US10195191B2 (en) 2011-12-15 2019-02-05 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
LT3153171T (lt) * 2011-12-15 2018-12-10 Alkermes Pharma Ireland Limited Samidorfanas (alks 33) derinyje su buprenorfinu, skirtas depresinių sutrikimų gydymui
ES2770978T3 (es) 2013-05-24 2020-07-06 Alkermes Pharma Ireland Ltd Análogos de morfanos y morfinanos y métodos de uso
EP3003311A2 (en) 2013-05-24 2016-04-13 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
ES2694352T3 (es) 2013-12-20 2018-12-20 H. Lundbeck A/S Uso de un antagonista del receptor opioide con actividad kappa, y vortioxetina para el tratamiento del trastorno depresivo con características melancólicas
EP4243768A1 (en) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5026556A (en) * 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
US4956171A (en) * 1989-07-21 1990-09-11 Paco Pharmaceutical Services, Inc. Transdermal drug delivery using a dual permeation enhancer and method of performing the same
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
EP0484543B1 (en) * 1990-04-24 1995-12-13 Teijin Limited Plaster
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US6165499A (en) * 1996-03-25 2000-12-26 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic system with small application-area thickness and great flexibility, and production process
US6787149B1 (en) * 1996-12-12 2004-09-07 El Khoury And Stein Ltd. Topical application of opioid analgesic drugs such as morphine
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
DE19738855C2 (de) * 1997-09-05 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht
DE19746191C2 (de) * 1997-10-18 2000-05-18 Lohmann Therapie Syst Lts Verfahren zur Anwendung eines Wirkstoff enthaltenden Pflasters zur Bekämpfung oder Linderung einer Sucht
US6242456B1 (en) * 1998-03-09 2001-06-05 Trustees Of Tufts College Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
DE19840758A1 (de) * 1998-09-07 2000-03-09 Liedtke Pharmed Gmbh Systemische Therapie von Schmerz- und depressiver Befindlichkeit

Similar Documents

Publication Publication Date Title
JP2005528359A5 (https=)
CY1107262T1 (el) Θεραπεια της εξαρτησης στερησης
DE69826644D1 (de) Topische pharmazeutische zusammensetzung, enthaltend einen cholinergischen wirkstoff oder einen kalziumkanalblocker
WO2001082914A3 (en) Topical anesthetic/opioid formulations and uses thereof
NO20001175D0 (no) Smertestillende blandinger omfattende anti-epileptiske forbindelser og fremgangsmÕter for anvendelse derav
JP2009544619A5 (https=)
UA88464C2 (ru) Способ дермального введения метадоновой композиции с обеспечением системного действия
DE60034667D1 (de) Pharmazeutische zusammensetzung aus komplexen kohlenhydraten deren anwendung
NZ592039A (en) Combination therapy for the treatment of ocular neovascular disorders
CY1108217T1 (el) Μεθοδος χορηγησης βουπρενορφινης για τη θεραπεια της καταθλιψης
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
JP2006513184A5 (https=)
DK1572167T3 (da) Transdermal buprenophindoseringsbehandlingsplan for analgesi
AU5706301A (en) Topical formulations for the transdermal delivery of niacin and methods of treating hyperlipidemia
CA2501738A1 (en) Method of treating chronic pelvic pain syndrome by administration of chrorionic gonadotropin
RU2002103808A (ru) Способ лечения болевого синдрома у онкологических больных
WO2003059284A3 (en) Composition and method for inhibiting hypersensitivity
JPWO2020079692A5 (https=)
WO2006117404A3 (de) Topische verwendung von radikalfangenden substanzen zur antipyretischen behandlung
Giusti et al. Alternative Routes for Systemic Opioid Delivery
WO2013096811A3 (en) Transmucosal drug delivery devices for use in chronic pain relief
RU2000105967A (ru) Способ лечения абстинентного синдрома у больных зависимостью от трамала
RU2007106415A (ru) Способ лечения тяжелой формы вульгарных угрей
RU2003115786A (ru) Способ лечения пневмонии у новорожденных
RU99105224A (ru) Способ местного лечения свищевого дерматита